1 hr ago
Lord's Mark Advances Radiation-Free AI Breast Screening Toward Final Trials
Lord's Mark and C-MET are developing a wearable device to help screen for breast cancer.
It does not use radiation.
Instead, it uses heat sensors and artificial intelligence to look for unusual temperature patterns.
The company has completed clinical trials in India.
More trials are planned in India, the United States, Great Britain and Europe.
These trials are expected to begin in January 2027.
The device still needs independent checks and approval from regulators.
If those steps are successful, the company hopes to make it available in April 2027.
Lord's Mark Industries and C-MET have advanced an AI-powered, radiation-free wearable breast cancer screening technology toward final clinical trials.
The device uses thermal sensors and AI-based temperature mapping to identify abnormal temperature patterns associated with breast cancer.
Trials are planned in India, the United States, Great Britain and Europe, with Phase 2 testing scheduled to begin in January 2027.
The company says Indian clinical trials have been completed, while regulatory evaluation and CDSCO approval remain in progress.
Lord's Mark is targeting completion of major clinical and regulatory milestones before March 2027 and commercial placement by April 2027, subject to approvals.
- Who
- Lord's Mark Industries Limited and the Centre for Materials for Electronic Technology developed the technology; Managing Director Sachidanand Upadhyay commented on the project.
- What
- An AI-powered, radiation-free wearable breast cancer screening device is moving toward final clinical trials.
- Where
- Trials and regulatory work involve India, the United States, Great Britain and Europe.
- When
- Indian trials have been completed; Phase 2 trials are planned from January 2027, with commercial placement targeted for April 2027.
- Why
- The technology is intended to detect breast cancer-related abnormalities earlier and expand affordable screening access, subject to successful validation and approvals.
Key facts
- Technology
- A battery-operated wearable using thermal sensors and AI-based temperature mapping.
- Radiation
- The device is designed to screen without radiation.
- Completed testing
- Clinical trials have been completed in India, with the company reporting accurate identification of evaluated cases.
- Planned trials
- Phase 2 trials targeting 98% accuracy are scheduled to begin in January 2027.
- Regulatory status
- Regulatory evaluation is ongoing in India, with CDSCO approval in process.
- Target milestones
- Lord's Mark is targeting completion of final trials and key regulatory milestones before March 2027.
- Commercial target
- Commercial placement is targeted for April 2027, subject to clinical validation and regulatory approvals.
Quotes
Sachidanand Upadhyay
Managing Director of Lord's Mark Industries Limited
“The approval of the final clinical trial stage marks an important milestone in taking this technology from innovation towards broader clinical validation. With successful trials already completed in India and further trials planned across the USA, Great Britain and Europe, our objective is to establish a robust clinical and regulatory pathway for an accessible, radiation-free and affordable breast cancer screening solution. We remain focused on taking this technology to a global platform,”
NDTV
Sources
Related news
Pune Health-Tech Firm Showcases Cervical Cancer AI at BRICS Exposition
India Showcases 37 Deep-Tech Innovations at BRICS 2026
AIIMS Transfers AI Mammography Technology to BPL Technologies
Pink Power Run Links Community Distance to Breast Cancer Screening
BRICS Summit Showcases 37 Indian Deep-Tech Innovations
IISc Startups Take Indian Deeptech From Lab to Market
India's Drug Regulator Warns Against Indiscriminate Painkiller, Antibiotic Use
CDSCO Warns About Painkillers That May Affect Kidneys
Bombay High Court Says Duty-Free Shops Must Follow Indian Laws
CDSCO Warns Against Unauthorised Pakistani Whitening Creams in India
